10 June 2025 in Frontiers in Oncology
Rhabdomyosarcoma (RMS) is a malignant tumor that is more common in children and rarely occurs in adults. Its prognosis mainly depends on the tumor stage and genetic type. In the past few decades, the survival rate of rhabdomyosarcoma has been significantly improved. Embryonal rhabdomyosarcoma (ERMS), alveolar rhabdomyosarcoma (ARMS), and pleomorphic rhabdomyosarcoma (PRMS) are common types of rhabdomyosarcoma. ERMS and ARMS are more common in children, while PRMS is more common in adults and has a poor prognosis. We report a case of a 40-year-old patient with ARMS. His chief complaint was difficulty urinating. The diagnosis was confirmed by puncture biopsy of the prostate, and pelvic lymph node metastasis was already present at the time of diagnosis. The patient underwent seven courses of chemotherapy and proton therapy and five courses of adjuvant chemotherapy. Unfortunately, 8 months after proton beam therapy, the patient showed disease progression (bone metastasis). This case illustrates the difficulties in managing late-stage prostatic alveolar rhabdomyosarcoma and is the first case reported in our hospital to be treated with proton beam therapy in an adult with ARMS of the prostate.
4 March 2026 in Frontiers in Oncology
Purpose: To compare the differences in dosimetry and toxicities between Magnetic Resonance Imaging (MRI) and Computed Tomography (CT)-guided intracavitary and interstitial implantation for locally advanced cervical cancer, respectively. Methods: We analyzed 40 cases of locally advanced cervical cancer admitted to our hospital from January 2023 to September 2024. Patients underwent CT-guided intracavitary and interstitial implantation followed by MRI scanning. We compared the volume of HR-CTV and IR-CTV, the dosimetric differences of HR-CTV D 90 and IR-CTV D 90 , and the dosimetric differences of D 2cc for the bladder, rectum, and small intestine under the two localization methods. Results: The mean HR-CTV and IR-CTV volumes were larger using CT guidance compared with MRI guidance (P<0.05), the differences were statistically significant. The HR-CTV D 90 and IR-CTV D 90 were smaller using CT than MRI guidance. The difference was statistically significant (P<0.05). There was a statistically significant difference in the rectum D 2cc between CT and MRI guidance (P0.05). Conclusion: Intracavitary and interstitial implantation under MRI guidance can significantly improve HR-CTV and IR-CTV D 90 with reduced target volume and good protection of the rectum, and there is no significant difference for the bladder and small intestine.
27 February 2026 in Frontiers in Oncology
The primary treatment for hilar cholangiocarcinoma is a surgical resection. However, most patients have already lost the opportunity for surgical treatment at the time of the initial diagnosis. Photon therapy (X-ray) has limited efficacy, whereas proton beam therapy (PBT) can improve local control. However, when tumors are located near the gastrointestinal tract, the therapeutic effect remains limited. Space-making particle therapy (SMPT) has emerged as a strategy to address the clinical challenge of high-dose radiation exposure to nearby organs at risk (OARs). This technique involves the surgical implantation of a bioabsorbable spacer prior to particle therapy delivery. Therefore, we are interested in the use of SMPT to preserve the gastrointestinal tract. A 77-year-old man with hilar cholangiocarcinoma underwent placement of a bioabsorbable spacer and then received radical PBT of 72.6 Gy (relative biological effectiveness, RBE) in 22 fractions. Surgery was not included in the original treatment plan. However, approximately 5 months after completing PBT, the patient developed biliary fluid accumulation, which subsequently required surgical intervention. Notably, pathological examination of the resected irradiated field revealed a complete pathological response (pCR), providing direct evidence of the treatment efficacy. This report describes one of the first cases in which a bioabsorbable spacer was surgically placed to preserve the gastrointestinal tract during PBT. SMPT is an innovative solution for hilar cholangiocarcinoma adjacent to the gastrointestinal tract. This case demonstrated the early feasibility and short-term efficacy of SMPT, but long-term follow-up is needed.
3 May 2026 in Holistic Integrative Oncology
Purpose: To prospectively determine the incidence of grade 2 acute genitourinary (GU) toxicity after hypofractionated proton beam therapy (PBT) for localized prostate cancer. Methods: The protocol was approved by the institutional review board (IRB). Patients received 51.6 Gy (relative biological effectiveness (RBE)) delivered in 12 fractions over 3 weeks. The primary endpoint was the incidence of grade ≥ 2 acute GU toxicities within 3 months. Neoadjuvant androgen deprivation therapy (ADT) was administered to the intermediate-risk group, and neoadjuvant and adjuvant ADT were administered to high-risk group classified according to the National Comprehensive Cancer Network (NCCN) guideline. Results: From March 2021 to June 2024, 100 patients underwent hypofractionated PBT. The incidence of grade 2 acute GU toxicities (urinary frequency) was 8% (95% confidence interval [CI] 2.6–13.4), meeting the pre-specified continuation criterion. No grade ≥ 3 acute GU toxicities were observed. Furthermore, no grade ≥ 2 acute urinary retention, urinary pain, urinary urgency or hematuria were observed. Univariate analysis preliminarily suggested that compared with the high-risk group patients, the low- and/or intermediate-risk group patients had a higher trend of grade 2 GU toxicities (OR: 0.265 (95% CI 0.066–1.062), P = 0.055). Multivariate regression analysis further confirmed that the high-risk classification was associated with a significantly lower risk grade 2 GU toxicities (OR: 0.023 (95% CI 0.002–0.840), P = 0.042). Additionally, multivariate regression analysis confirmed that benign prostatic hyperplasia (BPH) was an independent influencing factor for grade 2 GU toxicity (OR: 0.040 (95% CI 0.003–0.582), P = 0.018). Conclusions: Our results indicate that hypofractionated PBT (51.6 Gy [RBE] in 12 fractions over 3 weeks) for localized prostate cancer provides acceptable acute GU toxicity rates. Long-term follow-up of the 300-patient expansion cohort is underway to evaluate late toxicities and long-term oncological efficacy.